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1Boston Healthcare Associates, Boston, MA, USA, 2European Centre of Pharmaceutical 
Medicine (ECPM), Basel, Switzerland, 3The Medicines Company, Zürich-Flughafen, 
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OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In 2009, over 18,000 PPCI procedures were performed in France. New 
antithrombotic therapies can potentially improve clinical outcomes and decrease costs. 
The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event rates 
(mortality and bleeding) compared to a heparin and GPI (HEP + GPI) regimen. The 
potential economic value of implementing bivalirudin in the PPCI setting is evaluated 
here from a French hospital perspective. METHODS: A budget impact model was 
developed to compare treatment of STEMI patients undergoing PPCI with either 
bivalirudin or HEP + GPI. Clinical data for the model were derived from the HORI-
ZONS trial database, and included 30-day event rates for major complications (non-
access site bleeding as deﬁned by trial protocol, Q-wave myocardial infarction, repeat 
PCI and coronary artery bypass graft procedures) and patient death. Non-access site 
bleeding was examined in light of decreased incidence of access site-related bleeding 
events associated with radial access PCI, a common practice in France. French cost 
and clinical practice data were derived from published sources. RESULTS: Overall 
average procedure and hospitalization cost per bivalirudin-treated patient (incorporat-
ing 7.2% provisional GPI use as per HORIZONS) was 38171, compared with 39201 
per HEP + GPI-treated patient. In extrapolating these beneﬁts to a typical French 
hospital of 200 PPCI patients per year, 2 deaths (1%), 3 minor non-access site bleeding 
events (1.4%), and 4 major non-access site bleeding events (1.9%) in patients would 
be averted if treated with bivalirudin. The total hospital budget impact of treating 200 
PPCI patients using a HEP + GPI based strategy is 1,840,2673. Introducing a bivali-
rudin-based strategy could save 3206,148 (11%) per year. CONCLUSIONS: Using a 
bivalirudin-based strategy in STEMI patients undergoing PPCI is associated with 
favorable clinical and economic outcomes when compared with HEP + GPI in a French 
hospital setting.
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ECONOMIC EVALUATION ON THE USE OF LEVOSIMENDAN IN 
PATIENTS WITH ACCUTE HEART FAILURE (AHF) IN THE  
MEXICAN CONTEXT
Mayen E, Cortina D
Abbott Laboratories de México, Mexico City, DF, Mexico
OBJECTIVES: Evaluate the economic impact of the use of Levosimendan compared 
to Dobutamine, in patients with Acute Heart Failure (AHF) in Mexico. METHODS: 
Literature review was conducted to compare the resource utilization for AHF patients. 
Further, a budget impact analysis was done to demonstrate economic advantages of 
using Levosimendan, compared to Dobutamine. An economic model was built based 
on days in general ward (GW) and intensive care unit (ICU) as parameters. The 
number of days in GW and/or ICU was multiplied by the cost per GW and ICU, taken 
from the Mexican Federal Authority data. RESULTS: Length of stay was shorter in 
case of Levosimendan treated patients compared to Dobutamine ones (2.88 vs. 3.22 
in ICU, and 4.15 vs. 5.74 in GW), according to the ALARM-HF study (abstract 
presented at the ESC-Hear Failure annual congress 2007, Germany). The medical costs 
per patient were US$7418 if treated with Levosimendan and US$8680 for a patient 
receiving Dobutamine, thus a US$1262 difference. In Mexico, the cost of the treatment 
of AHF patients is US$500 (1 vial) for Levosimendan and US$76 (10 vials) for Dobu-
tamine (US$424 difference). The ﬁnal result, including the cost of the drug, shows a 
difference of 838 USD per patient in favour of the treatment with Levosimendan. 
According to international and national literature, the eligible AHF population to 
receive inotropic treatment in Mexico is approximately 90,240. Assuming that the 
whole population were treated with Dobutamine, the total cost, would be US$790.1 
million. If treated with Levosimendan, the total would be US$714.8 million. This 
represents potential savings of US$75.6 USD million for the Mexican Public Health 
System. CONCLUSIONS: The use of Levosimendan, in comparison with Dobuta-
mine, has demonstrated to represent a very important source of potential savings for 
the Mexican public health system in patients with AHF.
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OBJECTIVES: To determine the cost-effectiveness of Heart Failure (HF) clinics com-
pared to standard care for HF patients in Ontario, Canada. METHODS: We per-
formed a cost-effectiveness analysis, with a 12-year time horizon, from the perspective 
of the Ontario Ministry of Health. We compared a standard care cohort, consisting 
of all patients admitted to hospital with HF in 2005, to a hypothetical cohort treated 
in HF clinics. Survival curves describing the natural history of HF were constructed 
using mortality estimates from EFFECT study. Survival beneﬁts and resource uptake 
associated with HF clinics were estimated from a meta-analysis of published trials. 
HF clinics costs were obtained by costing of a representative clinic in Ontario. Health-
related costs associated with physician visits, hospitalizations, emergency department 
visits, same day surgeries and medication use, were determined through linkage to 
administrative databases. Outcome measures included life expectancy, costs (in 2008 
CAD$) and the incremental cost-effectiveness ratio (ICER). A budget impact analyses 
was performed to estimate affordability. RESULTS: The systematic review determined 
that HF clinics were associated with a 29% reduction in all-cause mortality (risk ratio 
[RR] 0.71; 95% Conﬁdence Interval [CI] 0.56–0.91) but a 12% increase in hospital-
izations (RR 1.12; 95% CI 0.92–1.135). The cost of care in HF clinics was $52 per 
30 patient-days. Projected life-expectancy of HF clinic patients was 3.91 years, com-
pared to 3.21 years for standard care. The 12 year cumulative cost per patient in the 
HF clinic group was $66,532 versus $53,638 in the standard care group. The ICER 
was $18,259/life year gained. The average annual cost for HF clinic implementation 
was $17 million in Ontario. CONCLUSIONS: Multi-disciplinary HF clinics reduce 
mortality and increase life expectancy. Despite increasing overall costs due to increased 
late hospitalizations, HF clinics appear to be a cost effective way of delivering ambula-
tory care to HF patients.
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COMPARATIVE EFFECTIVENESS OF LOW-MOLECULAR-WEIGHT-
HEPARINS: META-ANALYSIS AND PHARMACOECONOMIC ASSAY
Kildonaviciute G1, Kadusevicius E1, Varanaviciene B2
1Kaunas Medical University, Kaunas, Lithuania, 2Kaunas Medical University Hospital, Kaunas, 
Lithuania
OBJECTIVES: To compare efﬁcacy, safety and consumption of low-molecular-weight 
heparins (LMWHs) in Lithuania and to develop pharmacoeconomic decision model 
based on meta-analysis data. METHODS: Review and meta-analysis of published 
randomized control trials which directly compared the safety and efﬁcacy of low 
molecular weight heparins (LMWH) i.e. Nadroparin, Enoxaparin, Dalteparin, was 
conducted by two independent reviewers using inclusion/exclusion criteria based on 
the objectives of research. Statistical software MedCalc was used to perform the 
estimations of the following values. We calculated the value of ﬁxed effects and 
random effects odds ratio (95% conﬁdence interval (CI)) for each trial for the com-
posite end point. Afterwards, pharmacoeconomic decision modelling was imple-
mented, which was based on meta-analysis data. Cost-minimization assay was 
accomplished using reference pricing methodology. RESULTS: Enoxaparin vs. Dalte-
parin: 4 studies, involving 471 patients, were eligible (ﬁxed effects odds ratio 1.447 
[95% CI 0.957–2.281]). Nadroparin vs. Enoxaparin: 3 studies, involving 1118 
patients, were involved (ﬁxed effects odds ratio 1.360 [95% CI 1.050–1.762]). Dalte-
parin vs. Nadroparin: 2 studies, involving 294 patients, were eligible (ﬁxed effects 
odds ratio 0.577 [95% CI 0.337–0.988]). None of low-molecular-weight heparins 
demonstrated signiﬁcant superiority when compared with each other, so group of 
LMWHs was suitable for pharmacoeconomic analysis and reference pricing imple-
mentation. Dalteparin single DDD price was set as reference price, as it was the least 
expensive option. Introducing the reference pricing for low-molecular-weight heparins 
would result in total savings of 1,830–2,070 thousand LTL in Lithuania yearly. The 
implementation of reference pricing would enable to decrease the total expenditures 
on LMWHs by 29.28%–31.98%. CONCLUSIONS: In the accomplished meta-anal-
ysis, none of low-molecular-weight heparins demonstrated signiﬁcant superiority 
when compared with each other. Meta-analysis results could be applied to support 
pharmacoeconomic decision-modelling and that would allow decreasing health-care 
expenditures in the whole country.
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OBJECTIVES: To estimate total costs of stay in a skilled nursing facility (SNF) to 
Medicare, beneﬁciaries, and private payors 1 year after a venous thromboembolism 
(VTE) event in patients with total hip/knee replacement (THR/TKR), and to compare 
costs of stays in short- versus long-term facilities. METHODS: Based on 2004–2006 
national Medicare claims, all fee-for-service Medicare patients older than age 65 years 
who underwent THR/TKR were identiﬁed. The 1-year follow-up cost of care for 
patients with a VTE event (including deep vein thrombosis [DVT] and/or pulmonary 
embolism [PE]) during initial hospitalization was calculated for stays in short- versus 
long-term facilities or SNFs. Individual costs were identiﬁed as Medicare cost, total 
cost to beneﬁciaries, and total cost to private payors. Costs were compared between 
patients with and without a VTE event. Risk adjustment was done using regression 
techniques, controlling for baseline characteristics between patients with and without 
VTE events. RESULTS: In patients who underwent THR/TKR (n = 155,197), 1.8% 
had postoperative VTE during initial hospitalization. Almost 70% (n = 1950) of these 
patients had DVT, 24% (n = 642) PE, and 6% (n = 153) both DVT and PE. Almost 
20% of patients with DVT, 6.3% with PE, and 8.5% with both DVT and PE were 
discharged to an SNF. The 1-year total cost of an SNF stay for patients with VTE 
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was signiﬁcantly higher: $8877 versus $7597; P = 0.001. In patients who had a VTE 
event, mean cost of care was almost 26% ($3906) and 17% ($1935) higher for stays 
in short—and long-term facilities, respectively; P = 0.001. On average, Medicare paid 
26% ($4057), 17% ($2102), and 17% ($1149) more due to VTE events for patients 
discharged to a short- or long-term facility or an SNF, respectively. CONCLUSIONS: 
Regardless of discharge status, VTE events during initial hospitalization for THR/TKR 
signiﬁcantly increase total costs of a 1-year stay.
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AN ASSESSMENT OF DIRECT COSTS OF SINGLE PILL VERSUS FREE 
COMBINATION ARB/CCB THERAPY IN PATIENTS WITH 
HYPERTENSION
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OBJECTIVES: To evaluate direct costs associated with the use of valsartan/amlodipine 
single pill combination (SPC) therapy versus angiotensin receptor blocker (ARB) plus 
calcium channel blocker (CCB) free combination (FC) therapy in hypertensive 
patients. METHODS: Administrative claims data from the HealthCore Integrated 
Research Database (HIRDTM) were used to identify patients with ≥1 hypertension 
claim (ICD-9 codes 401.xx-404.xx) and ≥1 ﬁll for valsartan/amlodipine SPC or ARB/
CCB FC during the intake period 7/1/2007—9/30/2008. Only patients with ≥6 months 
pre- and post-index health plan eligibility were selected. Total health care costs, 
medical costs and pharmacy costs were aggregated over the follow-up period and 
annualized. Generalized linear models were used to control for baseline differences 
between the SPC and FC therapy groups and to compare annualized total costs, 
medical costs and pharmacy costs between SPC and FC groups, respectively. 
RESULTS: A total of 1,226 patients were identiﬁed in the SPC group and 280 patients 
in the FC group. After controlling for baseline differences, the SPC cohort ($6,402) 
had signiﬁcantly lower total health care costs compared with patients in the FC cohort 
($7,758), p = 0.0096. Similarly, the SPC group had lower medical costs ($4,408 vs. 
$5,517, p = 0.0373) and lower annual pharmacy costs ($1,864 vs. $2,074, p = 0.0417) 
compared to FC patients. CONCLUSIONS: Annual total costs were $1,356 lower for 
patients taking valsartan/amlodipine single pill combination therapy as compared to 
patients taking ARB/CCB free combination therapy, suggesting that treatment of 
hypertensive patients with valsartan/amlodipine single pill combination therapy may 
result in cost savings compared to ARB/CCB free combination therapy.
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COMPLIANCE AND HEALTH CARE UTILIZATION AMONG PATIENTS 
WITH HYPERTENSION TREATED WITH SINGLE PILL VS. FREE 
COMBINATION ANTIHYPERTENSIVE THERAPY: U.S. NATIONAL AND 
STATE LEVEL RESULTS FROM A CLAIMS DATABASE ANALYSIS
Yang W1, Chang JR1, Kahler KH1, Fellers TS1, Orloff J1, Wu EQ2, Bensimon AG2, Fan 
CPS2, Yu AP2
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with select antihypertensive single-pill combination (SPC) vs. free combina-
tion (FC) therapies among adult hypertension patients at both the national and state 
level. METHODS: Adult hypertension patients initiated on SPC or FC with angioten-
sin receptor blocker (ARB) + calcium channel blocker, ARB + hydrochlorothiazide, 
or angiotensin-converting enzyme inhibitors + hydrochlorothiazide were identiﬁed in 
the MarketScan Database (2006–2008). Study outcomes during the 6-month study 
period included medication possession ratio (MPR), treatment discontinuation rates, 
inpatient and emergency room (ER) visits, and changes in health care costs (study 
period minus baseline). Multivariate regression models examined the effect of SPC (vs. 
FC) use and its regional variation on outcomes, controlling for demographics, comor-
bidities, prescription use, and health care utilization during the baseline period (6 
months pre-therapy initiation). Regression-adjusted differences in outcomes between 
SPC vs. FC patients and associated 95% conﬁdence intervals (CIs) were estimated for 
the average patient in the U.S. and within each state. RESULTS: Adjusting for baseline, 
SPC patients (N = 382,476) demonstrated signiﬁcantly higher MPR (difference = 9.4% 
[95% CI: 9.2%, 9.5%]) and were less likely to discontinue treatment (odds ratio = 
0.535 [95% CI: 0.528, 0.542]) than FC patients (N = 197,375) nationwide. SPC 
patients had signiﬁcantly less hospitalizations and ER visits than FC patients, including 
29% fewer cardiovascular-related hospitalizations (adjusted incidence rate ratio = 0.71 
[95% CI: 0.69, 0.72]). Compared to FC, SPC patients showed signiﬁcantly greater 
reductions post-therapy initiation in all-cause medical costs by −$208 (95% CI: −$302, 
−$114), but larger increases in hypertension-related prescription costs by $53 (95% 
CI: $51, $55). State-level results were generally consistent in magnitude and trend for 
compliance and utilization outcomes, with greater regional variation in costs. CON-
CLUSIONS: SPC was associated with signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits compared to FC in hypertension 
patients. Larger reductions in medical costs with SPC offset small increases in drug 
costs.
PCV53
ALISKIREN COMBINED WITH ANGIOTENSIN II-RECEPTOR BLOCKERS 
(ARB) RESULTED IN BETTER OUTCOMES COMPARED TO ARB 
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(ACEI): RESULTS FROM A CLAIMS DATABASE ANALYSIS
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with aliskiren + ARB vs. ARB + ACEI combination therapies among adult 
patients with hypertension. METHODS: Patients with hypertension (age≥18) initiated 
on combination therapy (≥15 days of overlap) with aliskiren + ARB or ARB + ACEI 
during July 2007-June 2008 were identiﬁed in the MarketScan Database. Study out-
comes were measured during the 6-month study period, including medication posses-
sion ratio (MPR), treatment discontinuation rates, resource utilization, and changes 
in health care costs (from 6-month baseline to study period). Risk-adjusted differences 
in outcomes between aliskiren + ARB vs. ARB + ACEI patients and their 95% conﬁ-
dence intervals (CIs) were estimated using multivariate regression models, controlling 
for demographics, comorbidities, prescription drug use, and health care resource 
utilization during the baseline period. RESULTS: Comorbidity proﬁles were similar 
between patients on aliskiren + ARB (N = 1,395) vs. ARB + ACEI (N = 16,507), 
though baseline resource utilization and costs were different between the cohorts. 
Adjusting for baseline characteristics, aliskiren + ARB patients demonstrated signiﬁ-
cantly higher MPR (difference = 15.2% [95% CI: 13.0%, 17.4%]) and lower discon-
tinuation rate (odds ratio = 0.43 [95% CI: 0.37, 0.51]) than ARB + ACEI patients. 
Aliskiren + ARB patients had fewer all-cause hospitalizations (adjusted incidence rate 
ratio [IRR] = 0.73 [95% CI: 0.61, 0.86]) and fewer all-cause emergency room (ER) 
visits (adjusted IRR = 0.72 [95% CI: 0.61, 0.85]) than ARB + ACEI patients; results 
for cardiovascular-related hospitalizations and ER visits were similar. Compared to 
ARB + ACEI patients, aliskiren + ARB patients had larger increases in prescription 
costs by $264 during the 6 months following therapy initiation (95% CI: $153, $375), 
but showed a trend in reducing total health care costs by −$583 (95% CI: −$2,409, 
$1,242) during the same 6-month period. CONCLUSIONS: Patients with hyperten-
sion initiated on aliskiren + ARB had signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits than those initiated on ARB + 
ACEI. Trends indicated greater reductions in total health care costs with aliskiren + 
ARB, despite increased prescription costs.
PCV54
THE INCIDENCE AND COST OF SURGICAL SITE INFECTION (SSI) FOR 
COMMON CARDIOTHORACIC SURGICAL PROCEDURES IN THE USA: A 
STUDY USING THE PREMIER PERSPECTIVE™ DATABASE (PPD)
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OBJECTIVES: The incidence and incremental additional cost of surgical site infections 
(SSIs) for common cardiothoracic surgical procedures are not well characterized. Our 
study was designed to estimate the cost of several higher volume inpatient cardiotho-
racic surgical procedures to better characterize the burden of SSIs to hospitals and the 
health care system. METHODS: The Premier Perspective™ Database (PPD) was used 
to estimate the incidence and costs for SSIs in several common cardiothoracic surgical 
procedures using ICD-9 codes discharged between Q2 2006 and Q1 2009 from the 
over 600 US hospitals included in the PPD. PPD is the largest hospital-based, service-
level comparative database in the USA providing detailed resource utilization and cost 
data categorized under a patients’ principal and secondary diagnosis procedure codes. 
Our study focused on high volume cardiothoracic surgical procedures including 
sternum closure (3 codes), CABG (3 codes), and valve replacement (4 codes) to better 
estimate the incidence and costs of SSIs and the added costs to the health care system. 
RESULTS: The incidence of coded SSIs ranged between 1.9% to 6.3%, while the 
incremental additional costs for each SSI ranged between $30,395 and $67,722. The 
magnitude, therefore, of increased costs for each SSI was 2- to 6-fold higher compared 
with not having an SSI, depending on the cardiothoracic surgical procedure. 
CONCLUSIONS: The incidence of SSIs in several common cardiothoracic surgical 
procedures were relatively small (1.9%-6.3%), however, the increased costs ranged 
from 2- to 6-fold higher per SSI representing a substantial economic burden to hos-
pitals in the US health care system. New health care interventions targeted towards 
reducing the incidence of SSIs for common cardiothoracic procedures along the 
patient-care continuum are likely to reduce costs in both the short and long-term for 
hospitals in the US health care system.
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DIFFERENCE IN OUTCOMES MEASURES OF PATIENTS WITH 
VALVULAR AND NON-VALVULAR ATRIAL FIBRILLATION
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OBJECTIVES: Real world outcomes differences between valvular and non-valvular 
atrial ﬁbrillation is unknown. We identiﬁed these patients from U.S. claims data and 
compared the main outcomes differences to determine the economic and clinical 
burden of the disease. METHODS: We used U.S. medical and pharmacy claims data 
from 2005–2007 for the analysis. Patients aged 65 years and older who have had 2 
or more primary diagnoses for atrial ﬁbrillation occurring within 30 days of one 
